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Abstract
Background: Mucin 1 (MUC1) contributes to the growth and metastasis of various cancers, including lung cancer,
and MUC1 gene length polymorphisms are associated with susceptibility to lung cancer and its prognosis. In contrast, the
association between rs4072037, a single nucleotide polymorphism in MUC1, and lung cancer has not been well studied.
Methods: In the present study, we determined the rs4072037 genotype and measured serum KL-6 levels to evaluate the
association between lung adenocarcinoma (ADC) and rs4072037 or serum KL-6 levels. DNA samples were available
for 172 patients and these were included in the genomic analyses. In addition, 304 patients were included in
the serum analyses. Furthermore, 276 healthy volunteers were included in both genomic and serum analyses.
Results: The rs4072037 genotype was not associated with susceptibility to lung ADC or its prognosis. Interestingly,
serum KL-6 levels significantly differed according to rs4072037 genotype in those with T1 or T2 (P < 0.001), N0 or N1
(P = 0.002) and M0 (P < 0.001), but not in those with T3 or T4 (P = 0.882), N2 or N3 (P = 0.616) and M1a or M1b (P = 0.
501). Serum KL-6 levels were significantly associated with the presence of lung ADC, as well as with its progression and
prognosis, indicating the crucial involvement of KL-6/MUC1 in the development of lung cancer and its progression.
Conclusion: Based on these findings, we conclude that rs4072037 does not have a significant impact on the
pathogenesis or prognosis of lung ADC, whereas serum KL-6 levels, which might reflecting the molecular length
of MUC1, are significantly associated with lung ADC.
Keywords: KL-6, MUC1, rs4072037, Lung adenocarcinoma
Background
Lung cancer is one of the most common malignant tumors
worldwide. Adenocarcinoma (ADC) is the most common
histological type of lung cancer in the United States,
Europe, and East Asia, including Japan [1]. Although novel
therapeutic targets and molecular-targeted agents have
been identified and applied in clinical settings, lung cancer
remains the leading cause of cancer death in the majority
of developed countries [2]. Thus, the identification of novel
diagnostic biomarkers and potential therapeutic target
molecules is urgently needed.
Several types of mucins, including mucin 1 (MUC1),
are known to contribute to the growth and metastatic
properties of various tumors. In addition to their anti-
adhesion functions, mucins can affect the transcriptional
profile of various gene products involved in cancer cell in-
vasion and metastasis by mediating signal-transduction
[3, 4]. These findings indicate the potential utility of
MUC1 as a diagnostic biomarker and/or therapeutic target
in lung cancer. We have previously demonstrated that
MUC1 variable numbers of tandem repeats (VNTR) poly-
morphism was significantly associated with susceptibility to
lung ADC and its prognosis [5]. However, it would be very
difficult to identify MUC1 gene length polymorphisms in
clinical practice. Thus, in the current study, we focused on
alternative potential biomarkers which can reflect the
VNTR polymorphism and are more easily detectable in the
clinical setting: rs4072037, a single nucleotide polymorph-
ism (SNP) in theMUC1 gene, and serum KL-6 levels.
rs4072037, a functional SNP in exon 2 of the MUC1
gene, regulates splicing site selection during the post-
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transcriptional regulation process [6]. It has also been
reported that rs4072037 is in linkage disequilibrium with
VNTR in MUC1 [7]. Furthermore, several studies have
reported an association between rs4072037 and suscepti-
bility to gastric cancer [8–10]. Although no significant
association has been demonstrated between rs4072037
and lung cancer, these previous studies suggest that
rs4072037 may play a role in the development of lung
ADC and its progression, and that rs4072037 may have
utility as a diagnostic and/or prognostic biomarker in
lung ADC.
We previously developed a murine IgG1 monoclonal
antibody (mAb), designated KL-6, by immunizing a
mouse with lung ADC VMRC-LCR cells [11]. The anti-
KL-6 mAb recognizes sialylated carbohydrates attached
to the core protein of MUC1 through the glycosylation
process [12]. KL-6 has been well investigated as a useful
diagnostic and prognostic biomarker for various intersti-
tial lung diseases [11, 13, 14]. Additionally, we have
demonstrated that KL-6 may be a prognostic biomarker
for non-small cell lung cancer patients who have been
treated with epidermal growth factor receptor tyrosine
kinase inhibitors or surgical resection [15, 16]. While
these findings were promising, the number of patients
evaluated in these two studies was relatively small. Fur-
thermore, the combined contribution of serum KL-6
with the other important prognostic predictors of lung
ADC, such as EGFR gene mutation status [17], was not
sufficiently evaluated in the previous studies.
The two aims of the present study were as follows: 1)
to assess whether rs407247, a SNP in the MUC1 gene, is
associated with lung ADC development or prognosis,
and 2) to assess whether KL-6, a carbohydrate associated
with MUC1, improves the predictive power of the other
predictive factors in patients with lung ADC. In this
study, we evaluated the different rs4072037 genotypes
and the serum levels of KL-6 in 354 patients with lung
ADC and 276 healthy volunteers (HVs).
Methods
Patients and clinical samples
Five hundred and fifty-two patients with previously un-
treated lung ADC which was pathologically diagnosed and
subsequently treated at Hiroshima University Hospital
(Hiroshima, Japan) between April 2003 and June 2012
were included in this study (Fig. 1). The inclusion criteria,
shown in Fig. 1, were almost identical to those described
in our previous studies [15, 16, 18–21]. Disease staging in
all 552 cases included computed tomography scans of the
chest and abdomen, bone scintigraphy or F-18 fluordeoxy-
glucose positron emission tomography, and magnetic res-
onance imaging of the head. The clinical or pathologic
TNM stage was determined according to the 7th edition
of the TNM classification of malignant tumors [22]. Two
hundred and seventy-six HVs who attended health check-
ups were also enrolled. The HVs had no history or current
diagnosis of malignancy or apparent lung disease. Serum
and peripheral venous whole blood samples were obtained
from patients and HVs at enrollment with their written in-
formed consents for using their samples and publishing
the data. Serum samples were available for 354 of the 552
patients with ADC and for all 276 HVs. Among the 354
patients with ADC, EGFR gene mutation status was
known for 304 patients that were included in the serum
analyses. In addition, DNA samples were available for 172
patients and these were also included in the genomic ana-
lyses (Table 1). This study was approved by the Ethics
Committee of Hiroshima University Hospital (IRB M33
Fig. 1 Flow diagram of patient selection. The flow diagram illustrating
the inclusion process of the patients with lung adenocarcinoma into
the study. Three hundred and four patients were included into serum
analysis and 172 patients were included into genomic analysis, with 122
patients included into both analysis
Table 1 Clinical characteristics







Subject number 354 172 304 276
Age 65.9 ± 0.6 63.8 ± 0.9 66.6 ± 0.6 49.9 ± 0.4
Gender, Male /
Female
195 / 159 95 / 77 164 / 140 228 / 48
Smoking, Yes / No 211 / 143 103 / 69 179 / 125 158 / 118
PS, ≤1 / ≥2 319 / 35 149 / 23 274 / 30




55 / 67 /
50
122 / 182 / 0
T factor, ≤2 / ≥3 237 / 117 105 / 67 207 / 97
N factor, ≤1 / ≥2 180 / 174 72 / 100 156 / 148
M factor, 0 / 1 189 / 165 78 / 94 160 / 144
PS performance status, ND not detected
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and 326) and conducted in accordance with the ethical
standards established by the Helsinki Declaration of 1975.
EGFR mutation status
EGFR mutation status was evaluated in 304 patients, for
whom serum samples were available, in one of the follow-
ing sample types: cytology liquid samples derived from
bronchoscopy or thoracentesis, paraffin-embedded trans-
bronchial lung biopsy samples, or surgically resected
tumor tissues. To evaluate EGFR mutations, the peptide
nucleic acid-locked nucleic acid polymerase chain reaction
clamp test that detects the G719C, G719S, G719A,
L858R, L861Q, and T790 M mutations and seven different
exon 19 deletions was used, as previously described [23].
DNA preparation and rs4072037 genotyping
DNA was extracted from peripheral venous whole blood
samples using the phenol-chloroform extraction and etha-
nol precipitation methods, as previously described [24–26].
The rs4072037 genotype was determined by real-time
polymerase chain reaction (PCR) using a commercially
available SNP genotyping assay (TaqMan SNP Genotyping
Assay C 27532642–10; Life Technologies Corp. Carlsbad,
CA, USA) and the Applied Biosystems 7500 Fast RT-PCR
System (Life Technologies Corp.)
Measurement of serum KL-6 levels
Serum KL-6 levels were measured with a sandwich-type
electrochemiluminescence immunoassay on a Picolumi
8220 Analyzer (Sanko Junyaku, Tokyo, Japan), as previ-
ously described [15, 16, 20, 27].
Statistical analysis
The numerical data were presented as the mean ± standard
error of the mean. The Mann–Whitney U-test was used
to analyze data between 2 groups; for 3 or more groups,
the Kruskal-Wallis test followed by multiple comparisons
using rank sums was performed [28]. When dividing
patients into clinical subgroups according to performance
status (PS) or TNM factors, we performed receiver operat-
ing characteristic (ROC) analysis and determined the ap-
propriate cut-off point to predict the prognosis of the
patients. Survival analysis was performed using the log-
rank test and Cox proportional hazards models. Concord-
ance (C)-statistics were used to evaluate and compare the
Cox models. To test for deviations from Hardy-Weinberg
equilibrium, genotype frequencies were determined by dir-
ect counting and the chi-square test or Fisher’s exact test
were used as appropriate. Allelic frequencies were calcu-
lated based on the genotype frequencies, and the associ-
ation between the minor G allele of rs4072037 and lung
ADC was tested using the chi-square test or Fisher’s exact
test. All statistical analyses were performed using SPSS for
Windows, version 18.0 (SPSS Inc. Chicago, USA).
Results
The rs4072037 genotype was not associated with
susceptibility to lung ADC or its prognosis
To investigate the association between rs4072037 and sus-
ceptibility to lung ADC and/or its prognosis, we extracted
DNA from peripheral venous blood samples and evalu-
ated the presence of the rs4072037 genotype in 172 ADC
patients and 276 HVs. The clinical characteristics of the
studied subjects are shown in Table 1. The HVs were pre-
dominantly male and relatively young, compared with pa-
tients with lung ADC. The characteristics of patients with
ADC included in the genomic analyses and those included
in the serum analyses were similar. As shown in Table 2,
the genotype distributions of rs4072037 were in Hardy–
Weinberg equilibrium for both patients and HVs
(P = 0.891 and P = 0.979, respectively). Unexpectedly, the
genotype distributions of rs4072037 did not differ signifi-
cantly between patients with ADC and HVs (P = 0.933).
This result was consistent even when we limited the pa-
tients to those with advanced stage disease (Table 2). In
addition, genotypes of rs4072037 showed no significant
association with the risk of lung ADC both in dominant
and recessive models (Table 3). According to the Kaplan-
Meier analysis, the mean survival times for patients with
AA, AG, and GG genotypes were 2416.8 ± 257.2 days,
1988.8 ± 232.5 days and 486.0 ± 206.8 days, respectively.
Patients with the GG genotype tended to have a poorer
prognosis than the other patients, although this was not
statistically significant according to the log-rank test
(P = 0.173). We also have to pay attention to the fact that
there was only 4 patients with the GG genotype.
Serum KL-6 levels varied according to the rs4072037
genotype in HVs and patients with early stage ADC, but
not in those with advanced disease
Next, we investigated the correlation between the
rs4072037 genotype and serum KL-6 levels. As shown in
Fig. 2a, there was a significant correlation between the
rs4072037 genotype and serum KL-6 levels in HVs, which
was in line with the results of previous studies [24, 29]. In
patients with lung ADC, a significant correlation between
the rs4072037 genotype and serum KL-6 levels was ob-
served in those with T1 or T2 (Fig. 2b, P < 0.001), N0 or
N1 (Fig. 2c, P = 0.002) and M0 (Fig. 2d, P < 0.001), but
Table 2 Genotype distributions of rs4072037
AA (%) AG (%) GG (%) HWE chi-square
Healthy volunteers 186 (67.4) 82 (29.7) 8 (2.9) 0.979 ref.
All patients 116 (67.5) 52 (30.2) 4 (2.3) 0.891 0.933
limited to ≥T3 46 (68.7) 21 (31.3) 0 (0) 0.376 0.367
limited to ≥N2 65 (65.0) 33 (33.0) 2 (2.0) 0.772 0.761
limited to ≥M1a 62 (66.0) 28 (29.8) 4 (4.2) 0.968 0.811
HWE Hardy-Weinberg equilibrium
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not in those with T3 or T4 (Fig. 2b, P = 0.882), N2 or N3
(Fig. 2c, P = 0.616) and M1a or M1b (Fig. 2d, P = 0.501).
Serum KL-6 levels were significantly elevated in patients
with lung ADC
To confirm the correlation between serum KL-6 levels
and the presence of lung ADC, we compared serum KL-
6 levels between 304 patients with ADC and 276 HVs.
As shown in Fig. 3a, serum KL-6 levels were significantly
higher in patients with ADC than in HVs (880.8 ± 166.3 U/
mL and 241.0 ± 5.2 U/mL, P < 0.001). In addition, high
serum KL-6 levels were associated with poor PS (P < 0.001,
Fig. 3b), and advanced T, N and M factors (P < 0.001,
P < 0.001 and P < 0.001, respectively; Fig. 3b). On the other
hand, serum KL-6 levels did not differ between patients
with ADC with wild-type EGFR and mutant EGFR status
(768.4 ± 170.4 U/mL and 1048.5 ± 327.7 U/mL, P = 0.920,
Additional file 1).
Table 3 rs4072037 genotype and the risk of lung adenocarcinoma
Dominant model Recessive model
OR (95% CI) P value OR (95% CI) P value
All patients 0.998 (0.665–1.498) 0.991 0.798 (0.237–2.690) 0.484
limited to ≥T3 0.943 (0.531–1.675) 0.843 0.971 (0.951–0.991) 0.172
limited to ≥N2 1.113 (0.687–1.802) 0.664 0.684 (0.143–3.275) 0.477
limited to ≥M1a 1.067 (0.650–1.750) 0.798 1.489 (0.438–5.062) 0.363
OR odds ratio, CI confidence interval
a b
c d
Fig. 2 Serum KL-6 according to the genotypes of rs4072037. The distributions of serum KL-6 levels according to the genotypes of rs4072037 a in
healthy volunteers, b in the patients with T1 or T2 (left panel) and with T3 or T4 (right panel), c in the patients with N0 or N1 (left panel) and with
N2 or N3 (right panel), and d in the patients with M0 (left panel) and with M1a or M1b (right panel). The horizontal bars represent the mean values.
***P < 0.001 (Mann-Whitney U test)
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Serum KL-6 levels significantly correlated with survival in
patients with lung ADC
We performed ROC analysis to evaluate the predictive
ability of serum KL-6 in patients with ADC. The area
under the curve for 1-year, 3-year, and 5-year survival was
0.698 (95% confidence interval [CI] = 0.618–0.778;
P < 0.001, Fig. 4a), 0.686 (95% CI = 0.622–0.749; P < 0.001,
Fig. 4b) and 0.656 (95% CI = 0.593–0.719; P < 0.001, Fig.
4c), respectively. The optimal cut-off value for serum KL-6
levels to discriminate between survivors and non-survivors
was set at 600 U/mL, in accordance with the ROC
analyses. According to the Kaplan-Meier analysis, the
mean survival times for patients with higher and lower
serum KL-6 levels were 777.8 ± 117.7 days and
2807.6 ± 224.2 days, respectively. Patients with higher
serum KL-6 levels had a significantly poorer prognosis
than those with lower serum KL-6 levels, as tested by the
log-rank test (P < 0.001, Fig. 4d). This result was confirmed
when we perform additional log-rank test stratified by me-
dian value of serum KL-6 (P < 0.001, Fig. 4e). To further
investigate the predictive ability of serum KL-6, we per-
formed Cox proportional hazards regression analysis with
a b
Fig. 3 Serum KL-6 according to the presence or the clinical stage of lung adenocarcinoma. The distributions of serum KL-6 levels according to a
the presence or absence of lung adenocarcinoma, b performance status and TNM classifications are presented as scattered plots. HVs, healthy volunteers;




Fig. 4 Serum KL-6 can predict the outcome of patients with lung adenocarcinoma. Receiver operating characteristic curves for (a) 1-year, (b) 3-year,
and (c) 5-year survival. The Kaplan-Meier survival curves for each cohort stratified by the two different cut-off value of serum KL-6; (d) 600 U/mL (set by
ROC analyses), (e) 334 U/mL (median value)
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stepwise selection including both patients with mutant
EGFR and those with wild type EGFR. The initial covari-
ates included age, gender, smoking history, PS, EGFR mu-
tation status, TNM classifications and serum KL-6 levels.
As shown in Table 4A, there was a significant association
between serum KL-6 levels and prognosis in patients with
ADC, independent of the other covariates (PS, EGFR mu-
tation status, and N and M factors). In addition, this result
was not changed when we forcibly include age or gender
into the covariates (data not shown). Furthermore, com-
parison of the C-statistics of each prediction model, with
or without serum KL-6, demonstrated a significant in-
crease in C-index with the addition of serum KL-6 to the
other covariates (Table 4B).
Discussion
In the present study, no significant association was
found between the rs4072037 genotype and susceptibil-
ity to lung ADC or its prognosis. rs4072037 genotype
significantly affected serum KL-6 levels in patients with
early stage ADC, but not in those with advanced disease.
Furthermore, we demonstrated that serum KL-6 levels
were significantly associated with the presence of lung
ADC and its prognosis.
Although theMUC1 VNTR polymorphism is associated
with susceptibility to lung ADC and its prognosis [5], we
found that rs4072037, a SNP in the MUC1 gene, was not
associated with susceptibility to lung ADC or with its
prognosis. MUC1 is known to inhibit E-cadherin-
mediated cell-cell adhesion and integrin-mediated cell-
extracellular matrix adhesion [30, 31]. It is also known
that MUC1 is involved in the growth and metastasis of
various tumors, mainly due to its anti-adhesion and
signal-transduction functions [3, 4]. We have previously
reported that lung ADC cells expressed high levels of KL-
6/MUC1 [16, 32] and that an anti-KL-6 mAb induced
capping of MUC1, thereby interfering with its anti-
adhesion function and inhibiting tumor proliferation [33].
On the basis of these previous findings, we hypothesized
that the rs4072037 genotype in MUC1 was associated
with susceptibility to lung ADC and/or its prognosis.
However, we failed to verify our hypothesis. The link be-
tween rs4072037 and the VNTR polymorphism, which
was reported in 1996 [7], has actually been challenged by
several recent studies. Imbert et al. reported that the
MUC1 VNTR polymorphism correlated with the
rs4072037 genotype in only 80% of dry eye cases [34]. A
similar result in patients with sarcoidosis was also re-
ported by Shigemura et al. [35]. Based on these findings,
we speculate that the VNTR polymorphism in MUC1, but
not the rs4072037 genotype, has a significant impact on
the pathogenesis and progression of lung ADC.
Interestingly, we found that the correlation between
the rs4072037 genotype and serum KL-6 levels, which
was previously reported [24, 29, 35], was significant in
HVs and in patients with early stage ADC, but not in
those with advanced ADC (Fig. 2). Serum KL-6 in pa-
tients with lung ADC, especially in those with advanced
disease, is considered to be predominantly derived from
lung cancer cells with a minor contribution from normal
type II pneumocytes, which are known to be major
source of serum KL-6 under normal conditions [16, 32].
In addition, serum KL-6 levels have been reported to be
influenced by the molecular size of MUC1 in healthy
controls or in patients with sarcoidosis [35]. However,
such a correlation has not been reported in patients with
lung cancer. Therefore, we can speculate that the
rs4072037 genotype has a significant impact on serum
KL-6 derived from normal type II pneumocytes, but not
on serum KL-6 derived from lung ADC cells. In cancer
cells, alterations in the glycosylation properties of mucins,
which encompass aberrant glycosylation of O-linked gly-
cans, are known to play an important role in tumorigen-
esis, tumor progression, and metastasis [36–41]. Serum
KL-6 levels in patients with lung ADC may be influenced
by the aberrant glycosylation of O-linked glycans in
MUC1 and also by the depolarized expression pattern of
MUC1 in lung ADC [12, 16]. The influence of these epi-
genetic factors may diminish the association between the
rs4072037 genotype and serum KL-6 levels in patients
with advanced ADC.
In the present study, we successfully confirmed that
serum KL-6 levels are independently associated with
prognosis in patients with lung ADC. Although the cor-
relation between serum KL-6 levels and disease progres-
sion or prognosis in patients with lung ADC has already
been reported [11, 15, 16], the results from the present
study are still of pivotal importance; we have demon-
strated that serum KL-6 is a significant prognostic factor
for lung ADC, independent of the other known prognos-
tic factors, including EGFR mutation status [17]. Based
Table 4 Impact of serum KL-6 on the prognosis of lung
adenocarcinoma
Variable HR 95% CI. P value
A. Multivariate Cox proportional hazards regression model
PS, ordinal 1.72 1.35–2.20 <0.001
EGFR, wild type / mutant 2.43 1.62–3.64 <0.001
N factor, ordinal 1.23 1.04–1.45 0.018
M factor, yes / no 3.33 2.02–5.48 <0.001
Serum KL-6, ≥600 / <600 U/mL 2.19 1.43–3.37 <0.001
B. Comparison of C statistics for each prediction model
Prediction model C index 95% CI. P value
Covariates only 0.776 0.722–0.830 Ref.
Covariates + serum KL-6 0.790 0.736–0.843 0.036
“Covariates” in C statistics included PS, EGFR mutation status, and N and M
factors. PS performance status
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on these data, it is clear that KL-6/MUC1 plays an im-
portant role in tumor cell growth, proliferation, and me-
tastasis. Therefore serum KL-6 may be an alternative
and useful biomarker; it can reflect the VNTR poly-
morphism in MUC1 and is more easily detectable in the
clinical setting.
This study had some limitations. First, the patient sam-
ple size was small, especially for the genomic analysis.
Considering the low frequency of the rs4072037 G allele,
we cannot exclude the possibility that the small number
of patients harboring the G allele influenced the results.
Second, age and sex distributions differed between
patients and HVs. Despite these limitations, the results
from our study are quite evocative and provide important
insight into the crucial involvement of KL-6/MUC1 in the
development of lung cancer and its progression.
Conclusions
In conclusion, we demonstrated that rs4072037, a SNP
in MUC1 gene, does not affect lung ADC development
or its prognosis. We also demonstrated that serum KL-6
levels were significantly associated with the presence of
lung ADC and its progression and prognosis, indicating
the crucial role of KL-6/MUC1 in the development of
lung cancer and its progression.
Additional files
Additional file 1: Serum KL-6 according to the presence or absence of
EGFR gene mutation. (PDF 20 kb)
Additional file 2: The dataset supporting the conclusions of this article
is available in this datasheet. (XLS 133 kb)
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